LIN vs SER · P/E 34, rev $33.99B vs rev $56.0K
Linde plc Ordinary Shares (LIN) versus Serina Therapeutics Inc (SER) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported SER revenue for 2024-12-31 was $56.0K. Net income was -$11.2M. Revenue was down 98.2% from 2023-12-31 to 2024-12-31. SER currently screens at market cap $29.7M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. SER currently screens at market cap $29.7M.
Not investment advice. Open the LIN and SER stock pages for the full models.
Not investment advice.